Drug Profile
Anti-IGF-1R monoclonal antibody - Genentech
Alternative Names: rhuMAb IGFRLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 19 Oct 2007 Phase-I clinical trials in Solid tumours in USA (IV)